Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents

An improved pharmacological composition of the type employing an iron oxide complex with a polyol or polyether, wherein the improvement comprises:

• a polyol or polyether iron oxide complex composition prepared at concentrations of between about 1 mg/kg of body weight to about 4 mg/kg of body weight in a total volume of biocompatible liquid from about 1 mL to about 15 mL and for a total single dose from about 50 mg to about 600 mg, wherein the pharmacological composition is capable of being parenterally administered to a subject at a rate substantially greater than 1 mL/min and wherein the iron oxide complex provides upon administration:
• minimal detectable free iron in the subject;
• and
• minimal incidence of anaphylaxis.

A method of treating a subject with an iron oxide complex, the method comprising:

• parenterally administering the complex formulated in a pharmaceutically acceptable formulation in a biocompatible liquid;
• effecting administration at a rate substantially greater than 1 mL/min;
• and
• providing an effective dose in the range of about 1 mg/kg of body weight to about 4 mg/kg of body weight in a total volume of biocompatible liquid of between about 1 mL and 15 mL so that minimal free iron and minimal anaphylaxis occurs.

A method of treating a subject with an autoclavable reduced carboxyalkylated polyol iron oxide complex having at least 750 μmole but less than 1500 μmole of carboxyalkyl groups per gram of polyol to a subject, the method comprising:

• parenterally administering the complex formulated in a pharmaceutically acceptable formulation in a biocompatible liquid;
• effecting administration at a rate substantially greater than 1 mL/min;
• and
• providing an effective dose in the range of about 1 mg/kg of body weight to about 4 mg/kg of body weight in a total volume of biocompatible liquid of between about 1 mL and 15 mL so that minimal free iron and minimal anaphylaxis occurs.

A method of treating a subject with an autoclavable carboxyalkylated polyether iron oxide complex having at least 750 μmole but less than 1500 μmole of carboxyalkyl groups per gram of polyether to a subject, the method comprising:

• parenterally administering the complex formulated in a pharmaceutically acceptable formulation in a biocompatible liquid;
• effecting administration at a rate substantially greater than 1 mL/min;
• and
• providing an effective dose in the range of about 1 mg/kg of body weight to about 4 mg/kg of body weight in a total volume of biocompatible liquid of between about 1 mL and 15 mL so that minimal free iron and minimal anaphylaxis occurs.

An improved pharmacological composition of the type employing an autoclavable reduced carboxyalkylated polyol iron oxide complex, wherein the improvement comprises:

• a reduced carboxyalkylated polyol iron oxide complex composition having at least 750 μmole but less than 1500 μmole of carboxyalkyl groups per gram of polyol, prepared at concentrations of between about 1 mg/kg of body weight to about 4 mg/kg of body weight in a total volume of biocompatible liquid from about 1 mL to about 15 mL and for a total single dose from about 50 mg to about 600 mg, wherein the pharmacological composition is capable of being parenterally administered to a subject at a rate substantially greater than 1 mL/min and wherein the iron oxide complex provides upon administration:
• minimal detectable free iron in the subject;
• and
• minimal incidence of anaphylaxis.

An improved pharmacological composition of the type employing an autoclavable carboxyalkylated polyether iron oxide complex, wherein the improvement comprises:

• a carboxyalkylated iron oxide complex composition having at least 250 μmole but less than 1500 μmole of carboxyalkyl groups per gram of polyether, prepared at concentrations of between about 1 mg/kg of body weight to about 4 mg/kg of body weight in a total volume of biocompatible liquid from about 1 mL to about 15 mL and for a total single dose from about 50 mg to about 600 mg, wherein the pharmacological composition is capable of being parenterally administered to a subject at a rate substantially greater than 1 mL/min and wherein the iron oxide complex provides upon administration:
• minimal detectable free iron in the subject;
• and
• minimal incidence of anaphylaxis.